Skip to main content
. Author manuscript; available in PMC: 2018 Aug 23.
Published in final edited form as: JCO Precis Oncol. 2018 Jul 13;2018:10.1200/PO.17.00235. doi: 10.1200/PO.17.00235

Fig 1.

Fig 1.

Comparison of rate of MDM2 amplification in the current report (N = 102,878 samples) versus in Genomics Evidence Neoplasia Information Exchange (GENIE; N = 13,473 samples).31 Data from GENIE were obtained as previously described.31 The 10 most common diagnoses that harbor MDM2 amplification from the current report were selected for the comparison. MDM2 amplifications were seen in 3.5% (3,650 of 102,878) of patients in the current report versus 5.5% (744 of 13,473) from GENIE. MDM2 amplification was most commonly seen in patients with liposarcoma (63.6% [332 of 522] in the current report and 69.1% [47 of 68] from GENIE); gallbladder, adenocarcinoma (11.1% [62 of 554] in the current report and 17.5% [seven of 40] from GENIE); sarcoma, not otherwise specified (10.7% [103 of 955] in the current report and 25.0% [four of 16] from GENIE); urothelial carcinoma (10.4% [198 of 1,898] in the current report and 10.7% [48 of 446] from GENIE); and lung, adenosquamous carcinoma (9.8% [17 of 173] in the current report and 9.0% [one of 11] from GENIE).